Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia

International Journal of Hematology

Volumn 87, Issue 4, 2008, Pages 414-421

  Koenecke, Christian ^a   Hofmann, Michael ^a   Bolte, Oliver ^a   Gielow, Peter ^a   Dammann, Elke ^a   Stadler, Michael ^a   Franzke, Anke ^a   Boerner, Anne Rose ^a   Eder, Matthias ^a   Ganser, Arnold ^a   Knapp, Wolfram ^a   Hertenstein, Bernd ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

Author keywords

Allogeneic stem cell transplantation; Leukemia; MDS; Radioimmunotherapy

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY CD66 RE 188; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RADIOISOTOPE; ANTIBODY; CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; RHENIUM;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; TREATMENT OUTCOME; ALLOTRANSPLANTATION; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; ANTIBODIES; ANTIGENS, CD; CELL ADHESION MOLECULES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECURRENCE; RHENIUM; RISK FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 46149106120     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0043-1     Document Type: Article

References (33)

1. Friesen C, Lubatschofski A, Kotzerke J, et al. Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging. 2003;30:1251-61.
2. Malek SN, Flinn IW. Incorporating monoclonal antibodies in blood and marrow transplantation. Semin Oncol. 2003;30:520-30.
3. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429-31.
4. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:1469-79.
5. Ghobrial I, Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology (Williston Park). 2004;18:623-30.
6. Rajendran JG, Fisher DR, Gopal AK, et al. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med. 2004;45:1059-64.
7. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-40.
8. Reske SN, Bunjes D, Buchmann I, et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med. 2001;28:807-15.
9. Kotzerke J, Glatting G, Seitz U, et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. J Nucl Med. 2000;41:531-7.
10. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98:565-72.
11. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol. 2002;9:316-21.
12. Pagel JM, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. The use of radioimmunoconjugates in stem cell transplantation. Bone Marrow Transplant. 2002;29:807-16.
13. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32:549-56.
14. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control. 2002;9:106-13.
15. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-8.
16. Knapp FF Jr, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med. 1994;21:1151-65.
17. Seitz U, Neumaier B, Glatting G, et al. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med. 1999;26:1265-73.
18. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-46.
19. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-22.
20. Luxton RW, Kunkler PB. Radiation nephritis. Acta Radiol Ther Phys Biol. 1964;2:169-78.
21. Klein SA, Hermann S, Dietrich JW, Hoelzer D, Martin H. Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies. Blood. 2002;99:2270-1.
22. Ringhoffer M, Blumstein N, Neumaier B, et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005;130:604-13.
23. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85:1122-31.
24. Reske SN, Karstens JH, Gloeckner W, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet. 1989;1:299-301.
25. Schubiger PA, Hasler PH, Novak-Hofer I, Blauenstein P. Assessment of the binding properties of Granuloszint. Eur J Nucl Med. 1989;15:605-8.
26. Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst. 1990;82:47-50.
27. Behr TM, Sharkey RM, Sgouros G, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591-610.
28. Rottinger EM, Bartkowiak D, Bunjes D, Wennauer R, Dohr D. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy. Strahlenther Onkol. 2003;179:702-7.
29. Lawton CA, Cohen EP, Murray KJ, et al. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant. 1997;20:1069-74.
30. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867-71.
31. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77:1660-5.
32. Alyea E, Neuberg D, Mauch P, et al. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002;8:139-44.
33. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party Blood. 1998;92:3599-604.